Tapewire

Nasdaq · USD

INKT

MiNK Therapeutics, Inc.

Export transactions ↓
Tapewire entity
52
SEC CIK
0001840229
Parsed reports
145

Last 12 months

Inside the activity.

0 purchase rows · 9 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202601
Mar 202605
Apr 202600
May 202600
Jun 202602
Jul 202600
Aug 202600
Sep 202600
Oct 202601

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
July 18, 2022 Filed Jul 21, 2022 19:21 UTC
WIINBERG ULFDirector
PurchaseCommon Stock 3,339 $1.33 $4,437.53
Disclosure

SEC source: 0000899243-22-026460 · doc4.xml · nonDerivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,639

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.31 - $1.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Read SEC document
March 09, 2022 Filed Mar 11, 2022 16:12 UTC
Baldoni JohnDirector
GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-22-010706 · doc4.xml · derivative · entry 1

Baldoni John · CIK 0001851248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
March 09, 2022 Filed Mar 11, 2022 21:16 UTC
Behner PeterDirector
GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-22-010708 · doc4.xml · derivative · entry 1

Behner Peter · CIK 0001851420 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
March 09, 2022 Filed Mar 11, 2022 21:08 UTC
WIINBERG ULFDirector
GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-22-010698 · doc4.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
March 09, 2022 Filed Mar 11, 2022 21:09 UTC GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-22-010700 · doc4.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
March 09, 2022 Filed Mar 11, 2022 21:11 UTC
Ryan BarbaraDirector
GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-22-010704 · doc4.xml · derivative · entry 1

Ryan Barbara · CIK 0001827169 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

Read SEC document
January 21, 2022 Filed Jan 25, 2022 17:19 UTC
van Dijk Marcus AntoniusChief Technology Officer
GrantStock Option (Right to Buy) · Derivative 62,500 $0.00 Strike: $3.12 $0.00
Disclosure

SEC source: 0000899243-22-003171 · doc4.xml · derivative · entry 1

van Dijk Marcus Antonius · CIK 0001881659 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2032-01-21

F1 · derivative.exercise_date: Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date.

Read SEC document
January 21, 2022 Filed Jan 25, 2022 22:20 UTC
Buell JenniferDirector · See Remarks
GrantStock Option (Right to Buy) · Derivative 679,800 $0.00 Strike: $3.12 $0.00
Disclosure

SEC source: 0000899243-22-003172 · doc4.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679,800

Underlying: Common Stock · 679,800 shares

Expires 2032-01-21

F1 · derivative.exercise_date: Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date.

Read SEC document
December 28, 2021 Filed Feb 14, 2022 21:05 UTC
ARMEN GARO HDirector
GiftCommon Stock 360,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-006140 · doc5.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,866,400

F1 · kind: This transaction is not a sale and involves a gift of securities to a charitable organization. These shares are subject to the IPO lock-up agreement.

Read SEC document
October 19, 2021 Filed Oct 20, 2021 23:37 UTC
AGENUS INC10% owner
ConversionConvertible Promissory Note · Derivative 5,451,958 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-040873 · doc4.xml · derivative · entry 3

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,451,958 shares

Expires 2022-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The shares were received upon the automatic conversion of a convertible promissory note issued to Agenus Inc. by the issuer upon completion of the Issuer's initial public offering. The conversion rate of the note was equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the common stock sold in the initial public offering.

F2 · price: The shares were received upon the automatic conversion of a convertible promissory note issued to Agenus Inc. by the issuer upon completion of the Issuer's initial public offering. The conversion rate of the note was equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the common stock sold in the initial public offering.

Read SEC document
October 19, 2021 Filed Oct 20, 2021 23:37 UTC
AGENUS INC10% owner
ConversionCommon Stock 5,451,958 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-040873 · doc4.xml · nonDerivative · entry 2

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,332,958

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The shares were received upon the automatic conversion of a convertible promissory note issued to Agenus Inc. by the issuer upon completion of the Issuer's initial public offering. The conversion rate of the note was equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the common stock sold in the initial public offering.

F2 · price: The shares were received upon the automatic conversion of a convertible promissory note issued to Agenus Inc. by the issuer upon completion of the Issuer's initial public offering. The conversion rate of the note was equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the common stock sold in the initial public offering.

Read SEC document
October 19, 2021 Filed Oct 20, 2021 23:37 UTC
AGENUS INC10% owner
PurchaseCommon Stock 1,400,000 $12.00 $16,800,000.00
Disclosure

SEC source: 0000899243-21-040873 · doc4.xml · nonDerivative · entry 1

AGENUS INC · CIK 0001098972 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,881,000

F1 · kind: The shares were purchased in this Issuer's initial public offering.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.